Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Unknown 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 2Vipoma 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Unknown Primary 1Insulinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT04276597 2023-03-10

PUTNET

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Withdrawn
CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡